STIM1 and familial pancreatic carcinoma: McAndrew et al. (2011) showed from 295 breast cancer microarray data, that patients with a STIM1-high profile demonstrated abnormal SOCE and poorer prognosis. Orai1 and STIM1 expression were enhanced in therapy-resistant other types of carcinoma cells also (Xie et al., 2015). Pharmacological inhibition of STIM1- mediated SOCE can surprisingly enhance chemotherapy mediated lung or pancreatic cancer regression (Li W. et al., 2013; Kondratska et al., 2014).